News
MONARCH 3: Abemaciclib plus AI boosts PFS in HR+/HER2- breast cancer
MADRID – The study was stopped for efficacy at the interim analysis and median PFS for abemaciclib plus letrozole or anastrozole has not yet been...
News
LORELEI sings praises of neoadjuvant taselisib/letrozole in ER+/HER2– breast cancer
MADRID – The overall response rate was 50% for 166 patients assigned to letrozole plus taselisib, compared with 39.3% for 168 patients assigned to...
News
COMBI-AD: Adjuvant combo halves relapses in BRAF V600-mutated melanoma
MADRID – The relapse-free survival curves separated early in the study, and at 1 year the rate of RFS was 88% among patients treated with the...
News
Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanoma
The rates of relapse-free survival were 71% at 12 months for patients assigned to adjuvant nivolumab, compared with 61% for adjuvant ipilimumab....
News
Osimertinib bests PFS achieved with standard care for EGFR-mutated NSCLC
More answers are needed about the final number of patients who are able to crossover to osimertinib, and about the mechanism and management of...
News
Off-the-shelf T cells used to treat viral infections after HSCT
Study suggests an effective way to get around the limitations of adoptive VST transfer.
News
Vitamin D level linked to post-alloSCT relapse risk in myeloma
Vitamin D deficiency was associated with greater risk of relapse and lower survival for patients with myeloid malignancies.
News
Lenalidomide maintenance boosts survival in de novo myeloma after ASCT
“The use of lenalidomide maintenance for transplantation-eligible patients can be considered a standard of care.”
News
Hospice care underused in older patients with de novo AML
Fewer than half of older adults with AML were enrolled in hospice,
News
Abiraterone plus ADT boosts prostate cancer survival
Two studies report on the STAMPEDE and LATITUDE trials that added abiraterone acetate to androgen deprivation therapy for the treatment of...
News
Four drugs better than three for myeloma induction
MADRID – Adding the proteasome inhibitor carfilzomib to induction regimens delivered quicker and deeper remissions.
News
Pembrolizumab takes on r/r PMBCL
LUGANO, SWITZERLAND – Keynote 170 investigators are enrolling adults with relapsed/refractory PMBCL who are either ineligible for ASCT following...
News
Avelumab induces response in Hodgkin lymphoma after failed allo-SCT
LUGANO, SWITZERLAND – The immune checkpoint inhibitor avelumab showed efficacy against classical Hodgkin lymphoma among patients with disease...
News
IMiD/Anti-CD20 combo induces complete responses in r/r NHL
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful”...